Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA September 600x60px
Document › Details

AstraZeneca plc. (7/27/17). "Press Release: H1 2017 Results".

Organisation Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product Imfinzi®
  Product 2 Lynparza®
Person Person Soriot, Pascal (AstraZeneca 201210– CEO before Roche COO Pharma Div before Genentech CEO)
     


Pascal Soriot, Chief Executive Officer, commenting on the results said:

“Our performance in the first half was in line with expectations as we experience the loss of exclusivity of Crestor and Seroquel XR in the US. We continued to deliver transformative science across the pipeline, particularly in Oncology. Imfinzi was launched in bladder cancer while we published practice-changing data in breast cancer for Lynparza, our first-in-class PARP inhibitor. In lung cancer, we strengthened our unique portfolio focused on both the genetic drivers of disease and immunotherapy. In the first half, we shared positive results for Imfinzi in the PACIFIC trial and reported more encouraging data for Tagrisso in patients with central nervous system metastases.

“I’m excited about our pipeline-driven transformation as we continue to deliver for shareholders on our strategy to return to sustainable long-term growth. In a pivotal year for AstraZeneca, we remain focused on realising the potential of our pipeline, growing our new launch medicines and bringing our strong science to patients.”


Downloads
H1 2017 Results announcement (PDF 2.1mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/H1/H1_2017_Results_announcement.pdf ]

H1 2017 Results presentation (PDF 1.4mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/H1/H1_2017_Results_Presentation.pdf ]

H1 2017 Results Clinical trials appendix (PDF 2.5mb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/H1/H1_2017_Results_Clinical_Trial_Appendix.pdf ]

H1 2017 Results Transcript (PDF 220kb) [ https://www.astrazeneca.com/content/dam/az/PDF/2017/H1/H1_2017_Results_transcript.pdf ]

   
Record changed: 2017-08-02

Advertisement

Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 600x60px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA September 120x180px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px